What drove the intraday spike in 6L9.F stock?

The spike to **€0.025** on 11 Feb 2026 was driven by concentrated buy orders and low liquidity. Volume was **3,500.00**, far above the **279.00** average. There was no confirmed corporate news tied to the move.

How does 6L9.F stock compare to healthcare peers?

6L9.F has negative EPS **-0.55** and a negative PE, while healthcare peers show positive earnings and higher PE averages near **30.90**. ViewRay’s valuation reflects development-stage status and higher execution risk.

What is Meyka AI’s view on 6L9.F stock price outlook?

Meyka AI's forecast model projects a fair value near **€0.065**, implying about **160.00%** upside from **€0.025**. Forecasts are projections and not guarantees. Monitor liquidity and earnings for confirmation.

Is 6L9.F stock suitable for long-term investors?

Long-term investors should weigh product adoption and margin improvement against negative operating margins and debt-to-equity **1.05**. Consider smaller initial positions until revenue growth and cash flow trends improve.

DE Stocks

6L9.F ViewRay up 2400% to €0.025 on XETRA: high volume flags trader interest

ByDanny Kontos February 11, 2026February 11, 2026

The 6L9.F stock price surged intraday on 11 Feb 2026, climbing to €0.025 after a sharp move of 2400.00%. Trading on XETRA in Germany, volume hit 3,500.00 shares versus an average of 279.00, producing a relative volume of 12.54. This activity reflects concentrated trading interest rather than a broad repricing given the stock’s recent trading range. We track ViewRay, Inc. (6L9.F) because such high-volume spikes can precede short-term volatility or liquidity windows for larger positions.